Related Experiment Video
Updated: Oct 11, 2025
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
MPO-ANCA-positive Microscopic Polyangiitis Following COVID-19 Infection
Soko Kawashima1, Mitsumasa Kishimoto1, Tomoya Hibino1
1Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Japan.
Abstract:
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic disease that causes vasculitis in various organs. Although the cause of the onset is unknown, infection has been reported to be a causative factor. The subsequent cytokine storm triggered by the immune response against SARS-CoV-2 infection has been reported to lead to symptoms being more severe. We herein report our experience with the onset of AAV following COVID-19 infection. We also report the course of anti-SARS-CoV-2 serum antibody titers following induction therapy, which suggests that vaccination and education concerning standard precautions are necessary in patients who require immunosuppressive therapy, even after COVID-19 infection.
Insights
This study reports a case of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) following COVID-19 infection. It highlights the need for vaccination and precautions in immunosuppressed patients post-infection.
Area of Science:
- Immunology
- Rheumatology
- Infectious Diseases
Background:
- Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease affecting various organs.
- Infections are recognized as potential triggers for AAV onset.
- Severe COVID-19 can induce a cytokine storm, potentially exacerbating autoimmune conditions.
Purpose of the Study:
- To report a case of AAV onset following SARS-CoV-2 infection.
- To describe the clinical course and serological antibody titers in a patient with AAV post-COVID-19.
- To emphasize preventive strategies for patients undergoing immunosuppressive therapy.
Main Methods:
- Case report detailing the clinical presentation and diagnosis of AAV.
- Monitoring of anti-SARS-CoV-2 serum antibody titers.
- Review of patient's treatment and outcomes.
Main Results:
- The patient developed AAV subsequent to a COVID-19 infection.
- The study observed the trajectory of anti-SARS-CoV-2 antibody levels during treatment.
- The findings underscore the complex interplay between viral infection and autoimmune responses.
Conclusions:
- COVID-19 infection can precipitate the onset of AAV in susceptible individuals.
- Maintaining high antibody titers post-infection does not preclude AAV development.
- Vaccination and adherence to standard precautions are crucial for immunosuppressed patients, even after recovery from COVID-19.
